Idenix defends nucleoside analogue patent in Norway appeal against Gilead
Clients Idenix Pharmaceuticals LLC
Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in an appeal related to the validity of an Idenix patent covering nucleoside analogs and prodrugs. Subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV. The patent covers Gilead's marketing of Sovaldi® and Harvoni® for treatment of Hepatitis C.
Idenix Pharmaceuticals LLC, et al. v. Gilead Sciences Europe Ltd., Case No. 14-117680ASD-BORG/02 (Borgarting Court of Appeal, Norway)